XTL Biopharmaceutica Valuation

XTLB Stock  ILS 5.80  0.60  11.54%   
At this time, the company appears to be fairly valued. XTL Biopharmaceuticals maintains a prevalent Real Value of S5.65 per share. The last-minute price of the company is S5.8. Our model calculates the value of XTL Biopharmaceuticals from analyzing the company fundamentals such as Shares Owned By Insiders of 16.20 %, return on equity of 0.38, and Current Valuation of 61.84 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
5.80
Please note that XTL Biopharmaceutica's price fluctuation is unstable at this time. Calculation of the real value of XTL Biopharmaceuticals is based on 3 months time horizon. Increasing XTL Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since XTL Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XTL Stock. However, XTL Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  5.8 Real  5.65 Hype  5.8
The real value of XTL Stock, also known as its intrinsic value, is the underlying worth of XTL Biopharmaceuticals Company, which is reflected in its stock price. It is based on XTL Biopharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of XTL Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
5.65
Real Value
11.90
Upside
Estimating the potential upside or downside of XTL Biopharmaceuticals helps investors to forecast how XTL stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XTL Biopharmaceutica more accurately as focusing exclusively on XTL Biopharmaceutica's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
0.295.8012.05
Details

XTL Biopharmaceutica Total Value Analysis

XTL Biopharmaceuticals is at this time forecasted to have takeover price of 61.84 M with market capitalization of 236.53 K, debt of 0, and cash on hands of 5.06 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the XTL Biopharmaceutica fundamentals before making investing decisions based on enterprise value of the company

XTL Biopharmaceutica Asset Utilization

One of the ways to look at asset utilization of XTL is to check how much profit was generated for every dollar of assets it reports. XTL Biopharmaceuticals maintains a negative usage of resources of -0.1 (%), losing S0.001001 for each shekel of resources held by the company. Unsuccessful asset utilization attests that the company is being less efficient with each shekel of resources it maintains. Specifically, asset utilization of XTL Biopharmaceuticals shows how unproductive it operates for each shekel spent on its resources.

XTL Biopharmaceutica Ownership Allocation

XTL Biopharmaceuticals retains a total of 514.21 Million outstanding shares. XTL Biopharmaceuticals maintains 16.2 (%) of its outstanding shares held by insiders and 0.0 (%) owned by institutional investors. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.

XTL Biopharmaceutica Profitability Analysis

Net Income was 435 K with profit before overhead, payroll, taxes, and interest of 0.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates XTL Biopharmaceutica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in XTL Biopharmaceutica and how it compares across the competition.

About XTL Biopharmaceutica Valuation

The stock valuation mechanism determines XTL Biopharmaceutica's current worth on a weekly basis. Our valuation model uses a comparative analysis of XTL Biopharmaceutica. We calculate exposure to XTL Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XTL Biopharmaceutica's related companies.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.

8 Steps to conduct XTL Biopharmaceutica's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates XTL Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct XTL Biopharmaceutica's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain XTL Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine XTL Biopharmaceutica's revenue streams: Identify XTL Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research XTL Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish XTL Biopharmaceutica's growth potential: Evaluate XTL Biopharmaceutica's management, business model, and growth potential.
  • Determine XTL Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate XTL Biopharmaceutica's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Complementary Tools for XTL Stock analysis

When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated